Sponsor Pipeline

Genmab Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
32
Active Trials
11
Recruiting
13
Phase 3
10
Disease Areas
8
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-15 NCT07604766
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of…
Recruitment opened
2026-08-15 NCT07604766
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of…
Trial sites reduced: 20 -> 17 locations
2026-08-05 NCT03917381
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Primary endpoint(s) modified
2026-08-05 NCT07288177
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell…
Trial sites expanded: 41 -> 57 locations
2026-08-05 NCT06191744
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral…
Enrollment closed, study ongoing
2026-08-05 NCT07166094
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's…
Trial sites expanded: 120 -> 147 locations
2026-07-21 NCT07564141
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to…
Recruitment opened
2026-07-21 NCT07702032
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and…
Recruitment opened
Active Trials by Phase
Phase 3
13
Phase 2
5
Phase 1/2
8
Phase 1
6
Active Trials — top 25 of 32
NCT IDTitleConditionStatus
Phase 3
NCT07166094 Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's… Endometrial Cancer Recruiting
NCT07225270 Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to… Ovarian Cancer Recruiting
NCT07564141 Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to… Platinum-Sensitive Ovarian Cancer Recruiting
NCT07604766 An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of… Platinum-resistant Ovarian Cancer Recruiting
NCT07702032 Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and… Left-sided Colorectal Cancer Recruiting
NCT05578976 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined… Diffuse Large B-Cell Lymphoma Active, Not Recruiting
NCT06508658 A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to… Diffuse Large B-Cell Lymphoma Active, Not Recruiting
NCT07226752 A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in… Diffuse Large B-Cell Lymphoma Active, Not Recruiting
NCT04628494 A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in… Diffuse Large B-cell Lymphoma Active, Not Recruiting
NCT05409066 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… Follicular Lymphoma (FL) Active, Not Recruiting
NCT06191744 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… Follicular Lymphoma (FL) Active, Not Recruiting
NCT06635824 Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of… PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC Active, Not Recruiting
NCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in… Platinum-resistant Ovarian Cancer Active, Not Recruiting
Phase 2
NCT07288177 Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell… Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT07539311 Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced… Gastrointestinal Cancers Recruiting
NCT05451810 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the… Diffuse Large B-Cell Lymphoma Active, Not Recruiting
NCT05117242 Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With… Non Small Cell Lung Cancer Metastatic Active, Not Recruiting
NCT05283720 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC)… Non-Hodgkin Lymphoma Active, Not Recruiting
Phase 1/2
NCT05579366 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/… High Grade Epithelial Ovarian Cancer Recruiting
NCT05201248 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC)… B-Cell Non-Hodgkin Lymphoma Active, Not Recruiting
NCT03625037 First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell… DLBCL Active, Not Recruiting
NCT03917381 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Solid Tumors Active, Not Recruiting
NCT04083599 GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors Malignant Solid Tumor Active, Not Recruiting
NCT04542824 Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or… Diffuse Large B Cell Lymphoma Active, Not Recruiting
NCT04623541 Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic… Relapsed/Refractory Chronic Lymphocytic Leukemia Active, Not Recruiting
See all 32 active Genmab trials with filters →
Disease Areas
Get alerts when Genmab's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free